Results 181 to 190 of about 42,495 (262)

ATOX1 alleviates radiation‐induced cardiac injury by modulating AMPK/NRF2 to inhibit myocardial oxidative stress and mitochondrial dysfunction

Journal of Cell Communication and Signaling, Volume 20, Issue 2, June 2026.
This study found that ATOX1 can alleviate radiation‐induced oxidative stress and mitochondrial damage, maintain mitochondrial function, and reduce oxidative stress by activating the AMPK/NRF2 signaling pathway, ultimately exerting a cardioprotective effect.
Wen Deng, Li Su
wiley   +1 more source

Heart failure diagnosis: Impacts of atrial fibrillation on the diagnostic marker NT-proBNP. [PDF]

PLoS Med
Chen Y, McDowell G, Lip GYH.
europepmc   +1 more source

Causal Effects of Hydrophilic Bile Acids on Carfilzomib‐Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1494-1502, June 2026.
Carfilzomib is highly effective in the treatment of multiple myeloma, but it has been associated with cardiovascular adverse events that impact patient outcomes. Our prior global metabolomic analyses indicated an association between hydrophilic bile acids and carfilzomib‐cardiotoxicity risk, although a causal relationship remained to be determined ...
Samia Shabnaz, Eric Farber‐Eger, Marwa Tantawy, Neyousha Shahisavandi, Timothy J. Garrett, Samuel M. Rubinstein, Michael G. Fradley, Mohammed E. Alomar, Danny DeAvila, Kenneth H Shain, R. Frank Cornell, Daniel Lenihan, Qing Lu, Quinn S Wells, Rachid C. Baz, Yan Gong   +15 more
wiley   +1 more source

Correlation of NT-proBNP With Duration of Hospital Stay in Patients With Heart Failure: A Retrospective Review. [PDF]

Cureus
Harshitha H, Hoskere KPL, Sreenivas M, Ym P.   +3 more
europepmc   +1 more source

Artificial intelligence-powered electrocardiogram is superior to NT-proBNP in predicting left ventricular systolic dysfunction in atrial fibrillation with rapid ventricular response. [PDF]

Heart Rhythm O2
Baqal O, Yee CI, Quillen J, Mee XC, Lim GK, Ayoub C, Arsanjani R, Sorajja D, Noseworthy P, El Masry HZ.   +9 more
europepmc   +1 more source

Changes in NT-proBNP Levels According to SGLT2 Inhibitor Use in Patients Hospitalized for Acute Heart Failure Decompensation: A Prospective Cohort Study. [PDF]

Life (Basel)
Fountoulakis PN, Theofilis P, Oikonomou E, Siasos G, Pallantza Z, Bounta M, Karakasis P, Vlachakis PK, Tsioufis K, Tousoulis D.   +9 more
europepmc   +1 more source

Mapping the Global Clinical Landscape of Pharmacological Therapies for Heart Failure With Preserved Ejection Fraction: An Analysis Based on ClinicalTrials.gov (2003–2025)

iMetaMed, Volume 2, Issue 2, June 2026.
This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou, Jingwei Zhao, Yuqian Tang, Tan Liu, Zhiao Zhang, Ziheng Wang, Han Shen   +6 more
wiley   +1 more source

Navigating the challenges of NT-proBNP result disclosure in clinical research. [PDF]

J Clin Transl Sci
Kent DA, Villegas-Downs M, Wilson A, Krishnan J, Gerald L.   +4 more
europepmc   +1 more source

The Role of Endothelin‐1 in Autoimmune Diseases: Mechanistic Insights and Therapeutic Targets

iNew Medicine, Volume 2, Issue 2, June 2026.
The Role of Endothelin‐1 in Autoimmune Diseases. NF‐κB: nuclear factor kappa‐B; MAPK: mitogen‐activated protein kinase; PI3K: phosphoinositide 3‐kinase; ROS: reactive oxygen species; CTGF: connective tissue growth factor; TGF‐β: transforming growth factor‐β.
Xun Gong, Zhenyu Wang, Suyin Yang, Kaige Gao, Xin Yang, Min Tang   +5 more
wiley   +1 more source

CCN2/CTGF-Driven Myocardial Fibrosis and NT-proBNP Synergy as Predictors of Mortality in Maintenance Hemodialysis. [PDF]

Int J Mol Sci
Ko WC, Chen CS, Chang YP, Wu CS, Yang HC, Chang JF.   +5 more
europepmc   +1 more source